by PRI | Jun 21, 2022 | Microbiome Product Developer
Nikole Kimes CEO & Founder Siolta Therapeutics is a clinical-stage biotech company on a mission to alleviate the suffering of millions impacted by chronic inflammatory diseases through novel microbiome-based medicines....
by PRI | Jun 20, 2022 | Microbiome Product Developer
Tomas de Wouters Co-Founder & CEO Pioneering the development of microbiome-based therapies using proprietary tools for their design and production....
by PRI | Jun 20, 2022 | Microbiome Product Developer
Katja Conrath Chief Scientific Officer Unlocking the full potential of the gut microbiome for development of effective therapeutics through our proprietary CORAL™ consortia optimization and single-process manufacturing technology....
by PRI | Jun 20, 2022 | Microbiome Product Developer
Adam Wilkinson VP Pre-Clinical Development Microbiome biomarker and drug development company with a world-leading microbiome analysis platform....
by PRI | Jun 20, 2022 | Microbiome Product Developer
Charlotte Storni Global Regulatory Strategy Lead Biopharma Inspired by nature and distinguished by our world-class bioscience and microbiome capabilities, IFF’s Health & Biosciences (H&B) division is a leading innovation partner for customers across a broad...
by PRI | Jun 20, 2022 | Microbiome Product Developer
Johan E.T. van Hylckama Vlieg CSO & Co-founder Freya™ is a clinical-stage company taking an innovative approach to women’s health, with microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of reproductive system diseases...
